Genfit (NASDAQ:GNFT) Shares Down 2% – Time to Sell?

Genfit S.A. (NASDAQ:GNFT)’s stock price was down 2% during mid-day trading on Friday . The company traded as low as $3.45 and last traded at $3.47. Approximately 7,808 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 8,393 shares. The stock had previously closed at $3.54.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Genfit in a report on Friday, February 7th.

Genfit Trading Down 2.0 %

The company’s fifty day moving average price is $3.74 and its two-hundred day moving average price is $4.40. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61.

Hedge Funds Weigh In On Genfit

A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC acquired a new stake in Genfit S.A. (NASDAQ:GNFT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned approximately 0.33% of Genfit as of its most recent SEC filing. Hedge funds and other institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.